SARASOTA, Fla., Nov. 11 /PRNewswire-FirstCall/ -- CPC of America, Inc. (CPC) , today launched its new Web site, www.CPCMedDevices.com, to provide the medical and investment communities with a wealth of information on the company and its investigational product, MedClose(TM). CPC is a company focused on innovating medical devices that deliver improved safety and effectiveness and enhance the quality of patient care in endovascular procedures. It is pursuing worldwide commercial applications for MedClose(TM), an extravascular closure system (VCS) intended for use with a biological sealant to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures.
The Web site features CPC’s panel of medical, research and technical advisors, which includes:
-- James R. Margolis, M.D., F.A.C.C., the pioneer of angioplasty in the Southeastern United States and the sixth person in the World to perform coronary angioplasty. He is American Board certified in Internal Medicine, Interventional Cardiology and Cardiovascular Disease.
-- Fred L. Ma, M.D., Ph. D., a board-certified neurosurgeon with more than 25 years of clinical experience and experience in the development and commercialization of more than 20 new drugs and medical devices.
-- Grace T. Bartoo, Ph. D., RAC, CBA, co-founder of Decus Biomedical with more than 25 years of seeing medical devices through clinical trials and regulatory approval.
-- Marc L. Bartoo, Ph. D., RAC, co-founder and technical services manager of Decus Biomedical, with expertise in regulatory affairs, design control, verification and validation.
-- Steve Jwanouskos, a regulatory and clinical consultant with more than 20 years of experience in the development of innovative medical technologies, including extensive expertise in the development of novel medical devices.
-- Gerhard Fromel, DIPL. Ing, the authorized European representative for CPC with more than 25 years of experience in medical research, development and regulatory affairs in the European Union.
Further, the Web site displays an animated demonstration of the MedClose(TM) VCS in action. The animation highlights the unique design features of the MedClose(TM) VCS, which are intended to allow for significant reduction in time to hemostasis and need for manual compression. The MedClose(TM) device is intended for use with any approved natural fibrin sealant, leaving no permanent implant behind.
CPC Chairman President and CEO Rod Shipman said, “As we move closer to commercialization, we have upgraded our Web site to ensure that the medical and investment communities understand both our company and our products. We
will continue to populate the site with additional content and our latest news to keep our important constituents well informed.”
About CPC
CPC of America, Inc. (CPC) is focused on designing, developing and commercializing innovative medical devices that deliver improved safety and effectiveness and enhance the quality of patient care in endovascular procedures. CPC’s is currently developing MedClose(TM), an investigational*- stage vascular closure system (VCS) that is intended to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures.
Forward Looking Statements
The statements contained in this press release that are not historical are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements, without limitation, regarding the Company’s expectations, beliefs, intentions or strategies regarding the future. Such forward-looking statements relate to, among other things: (1) the Company’s continuing development of its MedClose(TM) vascular closure system, (2) the Company’s expectations concerning regulatory approvals of the MedClose system and the commencement of revenue producing operations based on the sale or licensing of the MedClose, (3) the business relationship between the Company and its panel of advisors and the expected benefits to the Company from such relationship, and (4) the commencement of manufacturing of the MedClose system. These statements are qualified by important factors that could cause the Company’s actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) the Company’s ability to finance the continued development and commencement of manufacturing of the MedClose system, (2) Regulatory approvals of the MedClose system, (3) the general risks and uncertainties inherent in any business relationship such as the those entered into between the Company and its medical, research and technical advisors, and (4) those other risks and factors described from time to time in the Company’s reports filed with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-K for the year ended December 31, 2007 and subsequently filed Forms 10-Q and Forms 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
CONTACT: Lindsey Jurca, of FD for CPC of America, Inc., at +1-213-452-6459
Web site: http://www.cpca2000.com/
http://www.CPCMedDevices.com/